NEXN-AS1: A Potential Drug Target and Biomarker (G374987)

Target Name: NEXN-AS1

NCBI ID: G374987

Other Name(s): NEXN antisense RNA 1 | C1orf118

NEXN-AS1: A Potential Drug Target and Biomarker

NEXN-AS1, a non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its unique structure, function, andExpression pattern make it an attractive target for the development of new therapeutic strategies.

NEXN-AS1 is a 24.1-kb long non-coding RNA molecule that is expressed in various tissues and organs, including brain, spleen, heart, and pancreas. It is highly expressed in the brain and has been shown to be involved in the development and progression of neurodegenerative disorders. NEXN-AS1 has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival.

One of the most significant features of NEXN-AS1 is its ability to interact with various protein partners, including nuclear factor of activated T cells (NFAT), which is a transcription factor that regulates the expression of genes involved in cell adhesion, migration, and survival. The interaction between NEXN-AS1 and NFAT has been shown to play a role in the regulation of various cellular processes, including the development and progression of neurodegenerative disorders.

NEXN-AS1 has also been shown to be involved in the regulation of inflammation and immune responses. It has been shown to play a role in the regulation of T cell development and function, as well as the regulation of inflammation and immune responses. These functions are critical for the development of cancer and autoimmune diseases.

In addition to its potential drug target and biomarker properties, NEXN-AS1 has also been shown to have potential clinical applications. For example, NEXN-AS1 has been shown to be downregulated in various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that targeting NEXN-AS1 may be a promising approach for the development of new therapeutic strategies for these disorders.

Furthermore, NEXN-AS1 has also been shown to be involved in the regulation of various cellular processes that are involved in cancer development and progression. Its expression has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis, which are all critical for the development and progression of cancer.

In conclusion, NEXN-AS1 is a promising drug target and biomarker with potential for the development of new therapeutic strategies for a variety of diseases. Its unique structure, function, and Expression pattern make it an attractive target for the development of new therapeutic strategies. Further research is needed to fully understand the role of NEXN-AS1 in various diseases and to develop effective therapeutic strategies.

Protein Name: NEXN Antisense RNA 1

More Common Targets